Steve Seedhouse
Stock Analyst at Cantor Fitzgerald
(1.97)
# 3,164
Out of 5,046 analysts
6
Total ratings
66.67%
Success rate
0.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Steve Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XNCR Xencor | Assumes: Overweight | $40 | $14.18 | +182.19% | 1 | Oct 6, 2025 | |
| CAMP Camp4 Therapeutics | Initiates: Overweight | $7 | $3.80 | +84.21% | 1 | Oct 2, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Overweight | $39 → $40 | $20.41 | +96.03% | 1 | Aug 1, 2025 | |
| INVA Innoviva | Initiates: Overweight | $26 | $17.87 | +45.54% | 1 | Jul 11, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Overweight | $52 | $4.66 | +1,015.88% | 1 | Jul 11, 2025 | |
| HROW Harrow | Initiates: Overweight | $76 | $38.00 | +100.03% | 1 | Jul 11, 2025 |
Xencor
Oct 6, 2025
Assumes: Overweight
Price Target: $40
Current: $14.18
Upside: +182.19%
Camp4 Therapeutics
Oct 2, 2025
Initiates: Overweight
Price Target: $7
Current: $3.80
Upside: +84.21%
Apellis Pharmaceuticals
Aug 1, 2025
Maintains: Overweight
Price Target: $39 → $40
Current: $20.41
Upside: +96.03%
Innoviva
Jul 11, 2025
Initiates: Overweight
Price Target: $26
Current: $17.87
Upside: +45.54%
Tvardi Therapeutics
Jul 11, 2025
Initiates: Overweight
Price Target: $52
Current: $4.66
Upside: +1,015.88%
Harrow
Jul 11, 2025
Initiates: Overweight
Price Target: $76
Current: $38.00
Upside: +100.03%